Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2017

Jan 6, 2017

31949_dirs_2017-01-06_13c16054-1735-4f19-b16b-a53056275e12.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Novocure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2017-01-01

Reporting Person: Longsworth Todd Christopher (General Counsel)

Holdings (Non-Derivative)

Security Shares Ownership
Ordinary Shares 2022 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Options to Buy Ordinary Shares $6.72 2022-04-29 Ordinary Shares (82782) Direct
Options to Buy Ordinary Shares $7.03 2023-02-19 Ordinary Shares (41391) Direct
Options to Buy Ordinary Shares $7.04 2023-07-23 Ordinary Shares (59130) Direct
Options to Buy Ordinary Shares $7.73 2024-10-20 Ordinary Shares (44347) Direct
Options to Buy Ordinary Shares $14.37 2025-02-23 Ordinary Shares (44347) Direct
Options to Buy Ordinary Shares $11.46 2026-02-24 Ordinary Shares (30000) Direct

Footnotes

F1: Fully vested and currently exercisable as of the date hereof.

F2: Options to buy 31,041 ordinary shares are vested and currently exercisable as of the date hereof. The remaining 10,350 ordinary shares will vest and become exercisable on February 20, 2017, subject to Mr. Longsworth's continued employment through such date.

F3: Options to buy 44,346 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 14,784 ordinary shares will vest and become exercisable on July 24, 2017, subject to Mr. Longsworth's continued employment through such date.

F4: Options to buy 22,172 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 22,175 ordinary shares will vest and become exercisable in equal installments on each of October 22, 2017 and 2018, subject to Mr. Longsworth's continued employment through such dates.

F5: Options to buy 11,086 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 33,261 ordinary shares will vest and become exercisable in equal installments on each of February 25, 2017, 2018 and 2019.

F6: Options to buy 30,000 ordinary shares will vest and become exercisable in equal installments on each of February 24, 2017, 2018, 2019 and 2020, subject to Mr. Longsworth's continued employment through such dates.